Publikacje

2019

  1.  Firczuk M, Bajor M, Graczyk-Jarzynka A, Fidyt K, Goral A, Zagozdzon R. Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy. Cancer Lett. 2019 Dec 4. pii: S0304-3835(19)30601-9. doi: 10.1016/j.canlet.2019.11.037. [Epub ahead of print] PubMed PMID: 31811907.
  2. Rywik TM, Braniewska A, Kowalik I, Firczuk M, Kozar-Kaminska K, Wojciechowska A, Kasprzyk-Pawelec A, Sobieszczanska-Malek M, Leszek P, Rozentryt P, Zielinski T. Trajectory of the circulating endothelial progenitor cell levels and their association with acute rejection after heart transplantation. Pol Arch Intern Med. 2019 Nov 28. doi: 10.20452/pamw.15072. [Epub ahead of print] PubMed PMID: 31777401.
  3. Sosnowska A, Czystowska-Kuzmicz M, Golab J. Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response. Oncoimmunology. 2019 Aug 20;8(11):e1655370. doi: 10.1080/2162402X.2019.1655370. eCollection 2019. PubMed PMID: 31646104; PubMed Central PMCID: PMC6791438.
  4. Sieńko J, Teliga-Czajkowska J, Przytula E, Czajkowski K, Smolarczyk R, Nowis D. Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer. Ann Agric Environ Med. 2019 Sep 19;26(3):415-419. doi: 10.26444/aaem/105899. Epub 2019 Apr 1. PubMed PMID: 31559796.
  5. Bobrowicz M, Zagozdzon R, Domagala J, Vasconcelos-Berg R, Guenova E, Winiarska M. Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives. Cancers (Basel). 2019 Sep 24;11(10). pii: E1420. doi: 10.3390/cancers11101420. Review. PubMed PMID: 31554169; PubMed Central PMCID: PMC6826541.
  6. Mazur M, Dymek B, Koralewski R, Sklepkiewicz P, Olejniczak S, Mazurkiewicz M, Piotrowicz M, Salamon M, Jędrzejczak K, Zagozdzon A, Czestkowski W, Matyszewski K, Borek B, Bartoszewicz A, Pluta E, Rymaszewska A, Mozga W, Stefaniak F, Dobrzański P, Dzwonek K, Golab J, Golebiowski A, Olczak J. Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases. J Med Chem. 2019 Aug 8;62(15):7126-7145. doi: 10.1021/acs.jmedchem.9b00681. Epub 2019 Jul 23. PubMed PMID: 31291098.
  7. Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, Wolinska E, Gaj P, Grazul M, Pilch Z, Zerrouqi A, Graczyk-Jarzynka A, Soroczynska K, Cierniak S, Koktysz R, Elishaev E, Gruca S, Stefanowicz A, Blaszczyk R, Borek B, Gzik A, Whiteside T, Golab J. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019 Jul 5;10(1):3000. doi: 10.1038/s41467-019-10979-3. PubMed PMID: 31278254; PubMed Central PMCID: PMC6611910.
  8. Szczepaniak A, Machnicki M, Gniot M, Pępek M, Rydzanicz M, Płoski R, Kaźmierczak M, Stokłosa T, Lewandowski K. Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm. Int J Hematol. 2019 Jul;110(1):102-106. doi: 10.1007/s12185-019-02642-w. Epub 2019 Apr 11. PubMed PMID: 30977107.
  9. Sasi BK, Martines C, Xerxa E, Porro F, Kalkan H, Fazio R, Turkalj S, Bojnik E, Pyrzynska B, Stachura J, Zerrouqi A, Bobrowicz M, Winiarska M, Priebe V, Bertoni F, Mansouri L, Rosenquist R, Efremov DG. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. Leukemia. 2019 Oct;33(10):2416-2428. doi: 10.1038/s41375-019-0442-8. Epub 2019 Mar 14. PubMed PMID: 30872780.
  10. Fidyt K, Pastorczak A, Goral A, Szczygiel K, Fendler W, Muchowicz A, Bartlomiejczyk MA, Madzio J, Cyran J, Graczyk-Jarzynka A, Jansen E, Patkowska E, Lech-Maranda E, Pal D, Blair H, Burdzinska A, Pedzisz P, Glodkowska-Mrowka E, Demkow U, Gawle-Krawczyk K, Matysiak M, Winiarska M, Juszczynski P, Mlynarski W, Heidenreich O, Golab J, Firczuk M. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia. Mol Oncol. 2019 May;13(5):1180-1195. doi: 10.1002/1878-0261.12476. Epub 2019 Apr 5. PubMed PMID: 30861284; PubMed Central PMCID: PMC6487705.
  11. Wolosz D, Walczak A, Szparecki G, Dwojak M, Winiarska M, Wolinska E, Gornicka B. Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma. Eur J Histochem. 2019 Feb 18;63(1). doi: 10.4081/ejh.2019.2981. PubMed PMID: 30827083; PubMed Central PMCID: PMC6383041.
  12. Sienko J, Gaj P, Czajkowski K, Nowis D. Peroxiredoxin-5 is a negative survival predictor in ovarian cancer. Ginekol Pol. 2019;90(1):1-6. doi: 10.5603/GP.2019.0001. PubMed PMID: 30756364.
  13. Pilch Z, Tonecka K, Skorzynski M, Sas Z, Braniewska A, Kryczka T, Boon L, Golab J, Meyaard L, Rygiel TP. The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies. PLoS One. 2019 Jan 17;14(1):e0210796. doi: 10.1371/journal.pone.0210796. eCollection 2019. PubMed PMID: 30653571; PubMed Central PMCID: PMC6336379.
  14. Graczyk-Jarzynka A, Goral A, Muchowicz A, Zagozdzon R, Winiarska M, Bajor M, Trzeciecka A, Fidyt K, Krupka JA, Cyran J, Szczygiel K, Efremov DG, Gobessi S, Jagielski A, Siudakowska K, Bobrowicz M, Klopotowska M, Barankiewicz J, Malenda A, Lech-Maranda E, Miazek-Zapala N, Skarzynski PH, Domagala A, Golab J, Firczuk M. Inhibition of thioredoxin-dependent H(2)O(2) removal sensitizes malignant B-cells to pharmacological ascorbate. Redox Biol. 2019 Feb;21:101062. doi: 10.1016/j.redox.2018.11.020. Epub 2018 Nov 29. PubMed PMID: 30576925; PubMed Central PMCID: PMC6302138.
  15. Marusiak AA, Prelowska MK, Mehlich D, Lazniewski M, Kaminska K, Gorczynski A, Korwat A, Sokolowska O, Kedzierska H, Golab J, Biernat W, Plewczynski D, Brognard J, Nowis D. Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. Oncogene. 2019 Apr;38(15):2860-2875. doi: 10.1038/s41388-018-0618-0. Epub 2018 Dec 14. PubMed PMID: 30552384; PubMed Central PMCID: PMC6484767. 

2018

  1. Graczyk-Jarzynka A, Goral A, Muchowicz A, Zagozdzon R, Winiarska M, Bajor M, Trzeciecka A, Fidyt K, Krupka JA, Cyran J, Szczygiel K, Efremov DG, Gobessi S, Jagielski A, Siudakowska K, Bobrowicz M, Klopotowska M, Barankiewicz J, Malenda A, Lech-Maranda E, Miazek-Zapala N, Skarzynski PH, Domagala A, Golab J, Firczuk M. Inhibition of thioredoxin-dependent H(2)O(2) removal sensitizes malignant B-cells to pharmacological ascorbate. Redox Biol. 2019 Feb;21:101062. doi: 10.1016/j.redox.2018.11.020. Epub 2018 Nov 29. PubMed PMID: 30576925; PubMed Central PMCID: PMC6302138.
  2. Marusiak AA, Prelowska MK, Mehlich D, Lazniewski M, Kaminska K, Gorczynski A, Korwat A, Sokolowska O, Kedzierska H, Golab J, Biernat W, Plewczynski D, Brognard J, Nowis D. Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. Oncogene. 2019 Apr;38(15):2860-2875. doi: 10.1038/s41388-018-0618-0. Epub 2018 Dec 14. PubMed PMID: 30552384; PubMed Central PMCID: PMC6484767.
  3. Kiraga Ł, Cheda Ł, Taciak B, Różańska K, Tonecka K, Szulc A, Kilian K, Górka E, Rogulski Z, Rygiel TP, Król M. Changes in hypoxia level of CT26 tumors during various stages of development and comparing different methods of hypoxia determination. PLoS One. 2018 Nov 9;13(11):e0206706. doi: 10.1371/journal.pone.0206706. eCollection 2018. PubMed PMID: 30412628; PubMed Central PMCID: PMC6226158.
  4. Bajor M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, Firczuk M, Trzeciak L, Gaj P, Domagala A, Siernicka M, Zagozdzon A, Siedlecki P, Kniotek M, O'Leary PC, Golab J, Zagozdzon R. Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. Br J Cancer. 2018 Oct;119(7):873-884. doi: 10.1038/s41416-018-0263-y. Epub 2018 Oct 5. PubMed PMID: 30287919; PubMed Central PMCID: PMC6189216.
  5. Szczałuba K, Chmielewska JJ, Sokolowska O, Rydzanicz M, Szymańska K, Feleszko W, Włodarski P, Biernacka A, Murcia Pienkowski V, Walczak A, Bargeł E, Królewczyk K, Nowacka A, Stawiński P, Nowis D, Dziembowska M, Płoski R. Neurodevelopmental phenotype caused by a de novo PTPN4 single nucleotide variant disrupting protein localization in neuronal dendritic spines. Clin Genet. 2018 Dec;94(6):581-585. doi: 10.1111/cge.13450. Epub 2018 Oct 11. PubMed PMID: 30238967.
  6. Calisti L, Trabuco MC, Boffi A, Testi C, Montemiglio LC, des Georges A, Benni I, Ilari A, Taciak B, Białasek M, Rygiel T, Król M, Baiocco P, Bonamore A. Engineered ferritin for lanthanide binding. PLoS One. 2018 Aug 13;13(8):e0201859. doi: 10.1371/journal.pone.0201859. eCollection 2018. PubMed PMID: 30102720; PubMed Central PMCID: PMC6089422.
  7. Domagala A, Fidyt K, Bobrowicz M, Stachura J, Szczygiel K, Firczuk M. Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy. Int J Mol Sci. 2018 Aug 1;19(8). pii: E2256. doi: 10.3390/ijms19082256. Review. PubMed PMID: 30071644; PubMed Central PMCID: PMC6121368.
  8. Pilch Z, Tonecka K, Braniewska A, Sas Z, Skorzynski M, Boon L, Golab J, Meyaard L, Rygiel TP. Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment. Cancer Immunol Res. 2018 Aug;6(8):930-940. doi: 10.1158/2326-6066.CIR-17-0454. Epub 2018 Jul 18. PubMed PMID: 30021725.
  9. Chlebowska-Tuz J, Sokolowska O, Gaj P, Lazniewski M, Firczuk M, Borowiec K, Sas-Nowosielska H, Bajor M, Malinowska A, Muchowicz A, Ramji K, Stawinski P, Sobczak M, Pilch Z, Rodziewicz-Lurzynska A, Zajac M, Giannopoulos K, Juszczynski P, Basak GW, Plewczynski D, Ploski R, Golab J, Nowis D. Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica. 2018 Nov;103(11):1843-1852. doi: 10.3324/haematol.2018.190231. Epub 2018 Jul 12. PubMed PMID: 30002127; PubMed Central PMCID: PMC6278960.
  10. Taciak B, Białasek M, Braniewska A, Sas Z, Sawicka P, Kiraga Ł, Rygiel T, Król M. Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages. PLoS One. 2018 Jun 11;13(6):e0198943. doi: 10.1371/journal.pone.0198943. eCollection 2018. PubMed PMID: 29889899; PubMed Central PMCID: PMC5995401.
  11. Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21. PubMed PMID: 29784639; PubMed Central PMCID: PMC6034642.
  12. Pyrzynska B, Dwojak M, Zerrouqi A, Morlino G, Zapala P, Miazek N, Zagozdzon A, Bojarczuk K, Bobrowicz M, Siernicka M, Machnicki MM, Gobessi S, Barankiewicz J, Lech-Maranda E, Efremov DG, Juszczynski P, Calado D, Golab J, Winiarska M. FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology. 2018 Jan 25;7(5):e1423183. doi: 10.1080/2162402X.2017.1423183. eCollection 2018. PubMed PMID: 29721381; PubMed Central PMCID: PMC5927521.
  13. Spólnicka M, Zbieć-Piekarska R, Karp M, Machnicki MM, Własiuk P, Makowska Ż, Pięta A, Gambin T, Gasperowicz P, Branicki W, Giannopoulos K, Stokłosa T, Płoski R. DNA methylation signature in blood does not predict calendar age in patients with chronic lymphocytic leukemia but may alert to the presence of disease. Forensic Sci Int Genet. 2018 May;34:e15-e17. doi: 10.1016/j.fsigen.2018.02.004. Epub 2018 Feb 7. PubMed PMID: 29472117.
  14. Domagala A, Stachura J, Gabrysiak M, Muchowicz A, Zagozdzon R, Golab J, Firczuk M. Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy. BMC Cancer. 2018 Feb 20;18(1):210. doi: 10.1186/s12885-018-4126-y. PubMed PMID: 29463237; PubMed Central PMCID: PMC5819678.
  15. Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. PLoS Med. 2018 Feb 20;15(2):e1002505. doi: 10.1371/journal.pmed.1002505. eCollection 2018 Feb. PubMed PMID: 29462168; PubMed Central PMCID: PMC5819765.
  16. Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, Almåsbak H, Bajor M, Clement D, Brandt L, Önfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19. PubMed PMID: 29459477.
  17. Janyst K, Janyst M, Siernicka M, Lasek W. Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells. Oncol Rep. 2018 Apr;39(4):1999-2005. doi: 10.3892/or.2018.6248. Epub 2018 Feb 6. PubMed PMID: 29436692.
  18. Mazur M, Bartoszewicz A, Dymek B, Salamon M, Andryianau G, Kowalski M, Olejniczak S, Matyszewski K, Pluta E, Borek B, Stefaniak F, Zagozdzon A, Mazurkiewicz M, Koralewski R, Czestkowski W, Piotrowicz M, Niedziejko P, Gruza MM, Dzwonek K, Golebiowski A, Golab J, Olczak J. Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase. Bioorg Med Chem Lett. 2018 Feb 1;28(3):310-314. doi: 10.1016/j.bmcl.2017.12.047. Epub 2017 Dec 22. PubMed PMID: 29292229.
  19. Mazur M, Olczak J, Olejniczak S, Koralewski R, Czestkowski W, Jedrzejczak A, Golab J, Dzwonek K, Dymek B, Sklepkiewicz PL, Zagozdzon A, Noonan T, Mahboubi K, Conway B, Sheeler R, Beckett P, Hungerford WM, Podjarny A, Mitschler A, Cousido-Siah A, Fadel F, Golebiowski A. Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma. J Med Chem. 2018 Feb 8;61(3):695-710. doi: 10.1021/acs.jmedchem.7b01051. Epub 2018 Jan 11. PubMed PMID: 29283260.
  20. Tak T, Rygiel TP, Karnam G, Bastian OW, Boon L, Viveen M, Coenjaerts FE, Meyaard L, Koenderman L, Pillay J. Neutrophil-mediated Suppression of Influenza-induced Pathology Requires CD11b/CD18 (MAC-1). Am J Respir Cell Mol Biol. 2018 Apr;58(4):492-499. doi: 10.1165/rcmb.2017-0021OC. PubMed PMID: 29141155.
  21. Sokolowska O, Nowis D. STING Signaling in Cancer Cells: Important or Not? Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):125-132. doi: 10.1007/s00005-017-0481-7. Epub 2017 Jul 26. Review. PubMed PMID: 28748479; PubMed Central PMCID: PMC5851689. 

2017

  1.  Mazur M, Bartoszewicz A, Dymek B, Salamon M, Andryianau G, Kowalski M, Olejniczak S, Matyszewski K, Pluta E, Borek B, Stefaniak F, Zagozdzon A, Mazurkiewicz M, Koralewski R, Czestkowski W, Piotrowicz M, Niedziejko P, Gruza MM, Dzwonek K, Golebiowski A, Golab J, Olczak J. Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase. Bioorg Med Chem Lett. 2018 Feb 1;28(3):310-314. doi: 10.1016/j.bmcl.2017.12.047. Epub 2017 Dec 22. PubMed PMID: 29292229.
  2. Norum OJ, Fremstedal ASV, Weyergang A, Golab J, Berg K. Photochemical delivery of bleomycin induces T-cell activation of importance for curative effect and systemic anti-tumor immunity. J Control Release. 2017 Dec 28;268:120-127. doi: 10.1016/j.jconrel.2017.10.015. Epub 2017 Oct 16. PubMed PMID: 29042319.
  3. Mroczek S, Chlebowska J, Kuliński TM, Gewartowska O, Gruchota J, Cysewski D, Liudkovska V, Borsuk E, Nowis D, Dziembowski A. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Nat Commun. 2017 Sep 20;8(1):619. doi: 10.1038/s41467-017-00578-5. PubMed PMID: 28931820; PubMed Central PMCID: PMC5606997.
  4. Guglielmi V, Nowis D, Tinelli M, Malatesta M, Paoli L, Marini M, Manganotti P, Sadowski R, Wilczynski GM, Meneghini V, Tomelleri G, Vattemi G. Bortezomib-Induced Muscle Toxicity in Multiple Myeloma. J Neuropathol Exp Neurol. 2017 Jul 1;76(7):620-630. doi: 10.1093/jnen/nlx043. PubMed PMID: 28863457.
  5. Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla-Venezia N, Kozikowski M, Siernicka M, Miazek N, Zapala P, Domagala A, Bojarczuk K, Malenda A, Barankiewicz J, Graczyk-Jarzynka A, Zagozdzon A, Gabrysiak M, Diaz JJ, Karp M, Lech-Maranda E, Firczuk M, Giannopoulos K, Efremov DG, Laurenti L, Baatout D, Frenzel L, Malinowska A, Slabicki M, Zenz T, Zerrouqi A, Golab J, Winiarska M. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017 Oct 5;130(14):1628-1638. doi: 10.1182/blood-2016-08-736066. Epub 2017 Aug 22. PubMed PMID: 28830887.
  6. Sokolowska O, Nowis D. STING Signaling in Cancer Cells: Important or Not? Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):125-132. doi: 10.1007/s00005-017-0481-7. Epub 2017 Jul 26. Review. PubMed PMID: 28748479; PubMed Central PMCID: PMC5851689.
  7. Sieńko J, Lasek W, Teliga-Czajkowska J, Smolarczyk R, Czajkowski K. Potentialization of N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) cytotoxic activity by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in human ovarian cancer cells. Ginekol Pol. 2017;88(6):307-311. doi: 10.5603/GP.a2017.0064. PubMed PMID: 28727129.
  8. Winiarska M, Nowis D, Firczuk M, Zagozdzon A, Gabrysiak M, Sadowski R, Barankiewicz J, Dwojak M, Golab J. Selection of an optimal promoter for gene transfer in normal B cells. Mol Med Rep. 2017 Sep;16(3):3041-3048. doi: 10.3892/mmr.2017.6974. Epub 2017 Jul 14. PubMed PMID: 28713922; PubMed Central PMCID: PMC5548056.
  9. Muchowicz A, Wachowska M, Stachura J, Tonecka K, Gabrysiak M, Wołosz D, Pilch Z, Kilarski WW, Boon L, Klaus TJ, Golab J. Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice. Eur J Cancer. 2017 Sep;83:19-27. doi: 10.1016/j.ejca.2017.06.004. Epub 2017 Jul 11. PubMed PMID: 28709135.
  10. Lechowicz U, Gambin T, Pollak A, Podgorska A, Stawinski P, Franke A, Petersen BS, Firczuk M, Oldak M, Skarzynski H, Ploski R. Iterative Sequencing and Variant Screening (ISVS) as a novel pathogenic mutations search strategy - application for TMPRSS3 mutations screen. Sci Rep. 2017 May 31;7(1):2543. doi: 10.1038/s41598-017-02315-w. PubMed PMID: 28566687; PubMed Central PMCID: PMC5451398.
  11. Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8. PubMed PMID: 28481221; PubMed Central PMCID: PMC5451241.
  12. Graczyk-Jarzynka A, Zagozdzon R, Muchowicz A, Siernicka M, Juszczynski P, Firczuk M. New insights into redox homeostasis as a therapeutic target in B-cell malignancies. Curr Opin Hematol. 2017 Jul;24(4):393-401. doi: 10.1097/MOH.0000000000000351. Review. PubMed PMID: 28402987; PubMed Central PMCID: PMC5470855.
  13. Franaszczyk M, Chmielewski P, Truszkowska G, Stawinski P, Michalak E, Rydzanicz M, Sobieszczanska-Malek M, Pollak A, Szczygieł J, Kosinska J, Parulski A, Stoklosa T, Tarnowska A, Machnicki MM, Foss-Nieradko B, Szperl M, Sioma A, Kusmierczyk M, Grzybowski J, Zielinski T, Ploski R, Bilinska ZT. Titin Truncating Variants in Dilated Cardiomyopathy - Prevalence and Genotype-Phenotype Correlations. PLoS One. 2017 Jan 3;12(1):e0169007. doi: 10.1371/journal.pone.0169007. eCollection 2017. PubMed PMID: 28045975; PubMed Central PMCID: PMC5207678.
  14. Bujko M, Machnicki MM, Grecka E, Rusetska N, Matyja E, Kober P, Mandat T, Rydzanicz M, Płoski R, Krajewski R, Bonicki W, Stokłosa T, Siedlecki JA. Mutational Analysis of Recurrent Meningioma Progressing From Atypical to Rhabdoid Subtype. World Neurosurg. 2017 Jan;97:754.e1-754.e6. doi: 10.1016/j.wneu.2016.10.047. Epub 2016 Oct 15. PubMed PMID: 27756662. 

2016

  1.  Majewska A, Lasek W, Przybylski M, Dzieciqtkowski T, Mlynarczyk G. Interferon-α and inosine pranobex-mediated inhibition of reploication of human RNA viruses in vitro. Med Dosw Mikrobiol. 2016;68(1):64-71. PubMed PMID: 28146624.
  2. Bujko M, Machnicki MM, Grecka E, Rusetska N, Matyja E, Kober P, Mandat T, Rydzanicz M, Płoski R, Krajewski R, Bonicki W, Stokłosa T, Siedlecki JA. Mutational Analysis of Recurrent Meningioma Progressing From Atypical to Rhabdoid Subtype. World Neurosurg. 2017 Jan;97:754.e1-754.e6. doi: 10.1016/j.wneu.2016.10.047. Epub 2016 Oct 15. PubMed PMID: 27756662.
  3. Stachura J, Wachowska M, Kilarski WW, Güç E, Golab J, Muchowicz A. The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. Oncoimmunology. 2016 May 13;5(7):e1182278. doi: 10.1080/2162402X.2016.1182278. eCollection 2016 Jul. Review. PubMed PMID: 27622039; PubMed Central PMCID: PMC5006909.
  4. Majewska A, Lasek W, Janyst M, Młynarczyk G. IN VITRO INfIBITION OF HHV-1 REPLICATION BY INOSINE PRANOBEX AND INTERFERON-α. Acta Pol Pharm. 2016 May-Jun;73(3):637-44. PubMed PMID: 27476281.
  5. Eyileten C, Majchrzak K, Pilch Z, Tonecka K, Mucha J, Taciak B, Ulewicz K, Witt K, Boffi A, Krol M, Rygiel TP. Immune Cells in Cancer Therapy and Drug Delivery. Mediators Inflamm. 2016;2016:5230219. doi: 10.1155/2016/5230219. Epub 2016 Apr 24. Review. PubMed PMID: 27212807; PubMed Central PMCID: PMC4860248.
  6. Polak A, Kiliszek P, Sewastianik T, Szydłowski M, Jabłońska E, Białopiotrowicz E, Górniak P, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Nowis D, Gołąb J, Giebel S, Lech-Marańda E, Warzocha K, Juszczyński P. MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. PLoS One. 2016 May 19;11(5):e0155893. doi: 10.1371/journal.pone.0155893. eCollection 2016. PubMed PMID: 27196001; PubMed Central PMCID: PMC4872998.
  7. Gabrysiak M, Wachowska M, Barankiewicz J, Pilch Z, Ratajska A, Skrzypek E, Winiarska M, Domagala A, Rygiel TP, Jozkowicz A, Boon L, Golab J, Firczuk M. Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo. Oncol Rep. 2016 Jun;35(6):3151-8. doi: 10.3892/or.2016.4723. Epub 2016 Apr 1. PubMed PMID: 27035643; PubMed Central PMCID: PMC4872279.
  8. Wachowska M, Osiak A, Muchowicz A, Gabrysiak M, Domagała A, Kilarski WW, Golab J. Investigation of cell death mechanisms in human lymphatic endothelial cells undergoing photodynamic therapy. Photodiagnosis Photodyn Ther. 2016 Jun;14:57-65. doi: 10.1016/j.pdpdt.2016.02.004. Epub 2016 Feb 8. PubMed PMID: 26868051.
  9. Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10. PubMed PMID: 26864341; PubMed Central PMCID: PMC4850868.
  10. Majewska A, Lasek W, Janyst M, Młynarczyk G. Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro. Cent Eur J Immunol. 2015;40(4):395-9. doi: 10.5114/ceji.2015.56960. Epub 2016 Jan 15. PubMed PMID: 26862302; PubMed Central PMCID: PMC4737737.
  11. Trzeciecka A, Klossowski S, Bajor M, Zagozdzon R, Gaj P, Muchowicz A, Malinowska A, Czerwoniec A, Barankiewicz J, Domagala A, Chlebowska J, Prochorec-Sobieszek M, Winiarska M, Ostaszewski R, Gwizdalska I, Golab J, Nowis D, Firczuk M. Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. Oncotarget. 2016 Jan 12;7(2):1717-31. doi: 10.18632/oncotarget.6435. PubMed PMID: 26636537; PubMed Central PMCID: PMC4811492.
  12. Dabek B, Kram A, Kubrak J, Kurzawski M, Wojcik P, Machnicki MM, Stoklosa T, Rydzanicz M, Ploski R, Debiec-Rychter M. A rare mutation in a rare tumor--SMARCB1-deficient malignant glomus tumor. Genes Chromosomes Cancer. 2016 Jan;55(1):107-9. doi: 10.1002/gcc.22296. Epub 2015 Sep 22. PubMed PMID: 26391213.
  13. Tahamtan A, Tavakoli-Yaraki M, Rygiel TP, Mokhtari-Azad T, Salimi V. Effects of cannabinoids and their receptors on viral infections. J Med Virol. 2016 Jan;88(1):1-12. doi: 10.1002/jmv.24292. Epub 2015 Jun 25. Review. PubMed PMID: 26059175. 

2015

  1. Majewska A, Lasek W, Janyst M, Młynarczyk G. Inhibition of adenovirusmultiplication by inosine pranobex and interferon α in vitro. Cent Eur J Immunol.2015;40(4):395-9. doi: 10.5114/ceji.2015.56960. Epub 2016 Jan 15.
  2. Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, BreckpotK, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L,de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, GougeonML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV,Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van GoolS, Velotti F, Zitvogel L, Agostinis P. Molecular and TranslationalClassifications of DAMPs in Immunogenic Cell Death. Front Immunol. 2015 Nov20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.
  3. Majewska A, Lasek W, Młynarczyk G. [Inosine pranobex - cytotoxic activitiesand effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4),entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro]. Med DoswMikrobiol. 2015;67(2):107-13. Polish.
  4. Dudek-Perić AM, Gołąb J, Garg AD, Agostinis P. Melanoma targeting with theloco-regional chemotherapeutic, Melphalan: From cell death to immunotherapeuticefficacy. Oncoimmunology. 2015 May 29;4(12):e1054600. eCollection 2015 Dec.
  5. Dabek B, Kram A, Kubrak J, Kurzawski M, Wojcik P, Machnicki MM, Stoklosa T,Rydzanicz M, Ploski R, Debiec-Rychter M. A rare mutation in a raretumor--SMARCB1-deficient malignant glomus tumor. Genes Chromosomes Cancer. 2016Jan;55(1):107-9. doi: 10.1002/gcc.22296. Epub 2015 Sep 22.
  6. Wachowska M, Muchowicz A, Golab J. Targeting Epigenetic Processes inPhotodynamic Therapy-Induced Anticancer Immunity. Front Oncol. 2015 Jul 30;5:176.doi: 10.3389/fonc.2015.00176. eCollection 2015. Review.
  7. Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, Siernicka M,Rozanska M, Winiarska M. B-cell receptor signaling in the pathogenesis oflymphoid malignancies. Blood Cells Mol Dis. 2015 Oct;55(3):255-65. doi:10.1016/j.bcmd.2015.06.016. Epub 2015 Jul 11. Review.
  8. Siernicka M, Winiarska M, Bajor M, Firczuk M, Muchowicz A, Bobrowicz M,Fauriat C, Golab J, Olive D, Zagozdzon R. Adenanthin, a new inhibitor ofthiol-dependent antioxidant enzymes, impairs the effector functions of humannatural killer cells. Immunology. 2015 Sep;146(1):173-83. doi: 10.1111/imm.12494.Epub 2015 Jul 8.
  9. Tahamtan A, Tavakoli-Yaraki M, Rygiel TP, Mokhtari-Azad T, Salimi V. Effectsof cannabinoids and their receptors on viral infections. J Med Virol. 2016Jan;88(1):1-12. doi: 10.1002/jmv.24292. Epub 2015 Jun 25. Review.
  10. Lasek W, Janyst M, Wolny R, Zapała Ł, Bocian K, Drela N. Immunomodulatoryeffects of inosine pranobex on cytokine production by human lymphocytes. ActaPharm. 2015 Jun;65(2):171-80. doi: 10.1515/acph-2015-0015.
  11. Truszkowska GT, Bilińska ZT, Kosińska J, Śleszycka J, Rydzanicz M,Sobieszczańska-Małek M, Franaszczyk M, Bilińska M, Stawiński P, Michalak E, MałekŁA, Chmielewski P, Foss-Nieradko B, Machnicki MM, Stokłosa T, Ponińska J,Szumowski Ł, Grzybowski J, Piwoński J, Drygas W, Zieliński T, Płoski R. A studyin Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations. BMC Med Genet. 2015 Apr 3;16:21. doi: 10.1186/s12881-015-0167-0.
  12. Dudek-Perić AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S,Kiviluoto S, Winiarska M, Boon L, Mathieu C, van den Oord J, Stas M, Gougeon ML, Golab J, Garg AD, Agostinis P. Antitumor immunity triggered by melphalan ispotentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015Apr 15;75(8):1603-14. doi: 10.1158/0008-5472.CAN-14-2089. Epub 2015 Mar 11.
  13. Zagozdzon R, Golab J. Cancer stem cells in haematological malignancies.Contemp Oncol (Pozn). 2015;19(1A):A1-6. doi: 10.5114/wo.2014.47127. Review.
  14. Muchowicz A, Firczuk M, Wachowska M, Kujawa M, Jankowska-Steifer E, GabrysiakM, Pilch Z, Kłossowski S, Ostaszewski R, Golab J. SK053 triggers tumor cellsapoptosis by oxidative stress-mediated endoplasmic reticulum stress. BiochemPharmacol. 2015 Feb 15;93(4):418-27. doi: 10.1016/j.bcp.2014.12.019. Epub 2015Jan 6.
  15. Grzybowski M, Glodkowska-Mrowka E, Stoklosa T, Gryko DT. Correction toBright, Color-Tunable Fluorescent Dyes Based on π-Expanded Diketopyrrolopyrroles.Org Lett. 2015 Jan 16;17(2):394. doi: 10.1021/ol5035782. Epub 2015 Jan 2.

2014

  1. Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, BobrowiczM, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podszywalow-Bartnicka P,Pilch Z, Dabrowska-Iwanicka A, Juszczynski P, Efremov DG, Slabicki M, Zenz T, Le Roy A, Olive D, Rygiel TP, Leusen JH, Golab J. Inhibitors of SRC kinases impairantitumor activity of anti-CD20 monoclonal antibodies. MAbs. 2014;6(5):1300-13.doi: 10.4161/mabs.32106. Epub 2014 Oct 30.
  2. Nowis D, Malenda A, Furs K, Oleszczak B, Sadowski R, Chlebowska J, Firczuk M, Bujnicki JM, Staruch AD, Zagozdzon R, Glodkowska-Mrowka E, Szablewski L, Golab J.Statins impair glucose uptake in human cells. BMJ Open Diabetes Res Care. 2014Apr 26;2(1):e000017. doi: 10.1136/bmjdrc-2014-000017
  3. Mlynarczuk-Bialy I, Doeppner TR, Golab J, Nowis D, Wilczynski GM, Parobczak K,Wigand ME, Hajdamowicz M, Biały LP, Aniolek O, Henklein P, Bähr M, Schmidt B,Kuckelkorn U, Kloetzel PM. Biodistribution and Efficacy Studies of the ProteasomeInhibitor BSc2118 in a Mouse Melanoma Model. Transl Oncol. 2014 Oct24;7(5):570-9. doi: 10.1016/j.tranon.2014.07.002.
  4. Serda M, Kalinowski DS, Rasko N, Potůčková E, Mrozek-Wilczkiewicz A, Musiol R,Małecki JG, Sajewicz M, Ratuszna A, Muchowicz A, Gołąb J, Simůnek T, RichardsonDR, Polanski J. Exploring the anti-cancer activity of novel thiosemicarbazonesgenerated through the combination of retro-fragments: dissection of criticalstructure-activity relationships. PLoS One. 2014 Oct 16;9(10):e110291. doi:10.1371/journal.pone.0110291.
  5. Wachowska M, Gabrysiak M, Golab J. Epigenetic remodeling combined withphotodynamic therapy elicits anticancer immune responses. Oncoimmunology. 2014May 15;3:e28837.
  6. O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A,O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX,Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP, Zagozdzon R, Gallagher WM.Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-inducedsuppression and is a protein biomarker of favorable prognosis in breast cancer.Breast Cancer Res. 2014 Jul 10;16(4):R79. doi: 10.1186/bcr3691.  
  7. Mrozek-Wilczkiewicz A, Serda M, Musiol R, Malecki G, Szurko A, Muchowicz A,Golab J, Ratuszna A, Polanski J. Iron chelators in photodynamic therapyrevisited: synergistic effect by novel highly active thiosemicarbazones. ACS Med Chem Lett. 2014 Jan 23;5(4):336-9. doi: 10.1021/ml400422a.  2014 Apr10.   24900837;
  8. van den Borne P, Rygiel TP, Hoogendoorn A, Westerlaken GH, Boon L, Quax PH,Pasterkamp G, Hoefer IE, Meyaard L. The CD200-CD200 receptor inhibitory axiscontrols arteriogenesis and local T lymphocyte influx. PLoS One. 2014 Jun4;9(6):e98820. doi: 10.1371/journal.pone.0098820.
  9. Glodkowska-Mrowka E, Mrowka P, Basak GW, Niesiobedzka-Krezel J, Seferynska I, Wlodarski PK, Jakobisiak M, Stoklosa T. Statins inhibit ABCB1 and ABCG2 drugtransporter activity in chronic myeloid leukemia cells and potentiateantileukemic effects of imatinib. Exp Hematol. 2014 Jun;42(6):439-47. doi:
  10. Muchowicz A, Firczuk M, Chlebowska J, Nowis D, Stachura J, Barankiewicz J,Trzeciecka A, Kłossowski S, Ostaszewski R, Zagożdżon R, Pu JX, Sun HD, Golab J.Adenanthin targets proteins involved in the regulation of disulphide bonds.Biochem Pharmacol. 2014 May 15;89(2):210-6. doi: 10.1016/j.bcp.2014.02.022.
  11. Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR, Golab J. 5-Aza-2'-deoxycytidine potentiatesantitumour immune response induced by photodynamic therapy. Eur J Cancer. 2014May;50(7):1370-81. doi: 10.1016/j.ejca.2014.01.017. Epub 2014 Feb 18.
  12. Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promisingcandidate for tumor immunotherapy? Cancer Immunol Immunother. 2014May;63(5):419-35. doi: 10.1007/s00262-014-1523-1. Epub 2014 Feb 11. Review.
  13. Machnicki MM, Stoklosa T. BRAF--a new player in hematological neoplasms.Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):77-83. doi: 10.1016/j.bcmd.2014.01.001.Epub 2014 Feb 2.
  14. Glodkowska-Mrowka E, Solarska I, Mrowka P, Bajorek K, Niesiobedzka-Krezel J, Seferynska I, Borg K, Stoklosa T. Differential expression of BIRC family genes inchronic myeloid leukaemia--BIRC3 and BIRC8 as potential new candidates toidentify disease progression. Br J Haematol. 2014 Mar;164(5):740-2. doi:10.1111/bjh.12663.
  15. Kilarski WW, Muchowicz A, Wachowska M, Mężyk-Kopeć R, Golab J, Swartz MA,Nowak-Sliwinska P. Optimization and regeneration kinetics of lymphatic-specificphotodynamic therapy in the mouse dermis. Angiogenesis. 2014 Apr;17(2):347-57.doi: 10.1007/s10456-013-9365-6. Epub 2013 Jul 28.  

2007

1. Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, Seferynska I, Reiss K, Skorski T. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex RAD50-Mre11-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood. 2007 Apr 12; [Epub ahead of print]

2. Issat T, Nowis D, Legat M, Makowski M, Klejman MP, Urbański J, Skierski J, Koronkiewicz M, Stokłosa T, Brzezińska A, Bil J, Gietka J, Jakóbisiak M, Gołąb J. Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. International Journal of Oncology 2007, 30(6):1413-25

3. Bil J., Winiarska M.. Molekularne mechanizmy aktywności terapeutycznej rytuksymabu – przeciwciała monoklonalnego anty-CD20 Postępy biologii komórki 2007; Tom 34, NR 2 (335-359)

4. Kocanova S, Buytaert E, Matroule JY, Piette J, Golab J, de Witte P, Agostinis P. Induction of heme-oxygenase 1 requires the p38(MAPK) and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis. 2007;12(4):731-41.

2006

1. Kocanova S, Buytaert E, Matroule J-Y, Piette J, Golab J, de Witte P, Agostinis P. Heme oxygenase 1 induction by hypericin-mediated photodynamic therapy is regulated by the p38MAPK and PI3K pathways through the nuclear accumulation of NRF-2. Apoptosis (in press)

2. Issat T, Jakobisiak M, Golab J. Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effectsindependently from the mevalonate pathway. Oncol Rep. 2006; 16(6):1273-1276

3. Mlynarczuk-Bialy I, Roeckmann H, Kuckelkorn U, Schmidt B, Umbreen S, Golab J, Ludwig A, Montag C, Wiebusch L, Hagemeier C, Schadendorf D, Kloetzel PM, Seifert U. Combined effect of proteasome and calpaininhibition on cisplatin-resistant human melanoma cells. Cancer Res. 2006;66 (15): 7598-7605

4. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J, Skorski T. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006 Jul 1;108(1):319-27

5. Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczynski GM, Glodkowska E, Mrowka P, Issat T, Dulak J, Jozkowicz A, Was H, Adamek M, Wrzosek A, Nazarewski S, Makowski M, Stoklosa T, Jakobisiak M, Golab J. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene. 2006 Jun 8;25(24):3365-74
6. Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, Koptyra M, Seferynska I, Krszyna K, Blasiak J, Skorski T. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle. 2006 May;5(9):994-1000

7. Hareng L, Lasek W, Switaj T, Sienko J, Jakubowska AB, Nowaczyk M, Kasprzycka M, Kazimierczuk Z. TNF-alpha production-enhancing activity of 2-(1-adamantylamino)-6-methylpyridine (AdAMP) in cultures of human normal and neoplastic cells. Anticancer Res. 2006 Mar-Apr;26(2A):1209-15

2005

1. Krszyna K, Stokłosa T. Czynnik indukowany przez hipoksję-1 (HIF-1): Budowa, regulacja ekspresji, funkcja oraz rola w progresji nowotworów. Post Biol Kom. 2005; 32(4): 707-728

2. Nowis D, Stokłosa T, Legat M, Issat T, Jakóbisiak M, Gołąb J. The influence of PDT on the immune response. Photodiagn. Photodyn. Ther. 2005 (in press)

3. Ciechomska I, Legat M, Golab J, Wesolowska A, Kurzaj Z, Mackiewicz A, Kaminska B. Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies. Int J Cancer. 2005 Oct 20;117(1):59-67

4. Stoklosa T, Golab J. Prospects for p53-based cancer therapy. Acta Biochim Pol. 2005;52(2):321-8. Epub 2005 Jun 25

5. Nowis D, Makowski M, Stoklosa T, Legat M, Issat T, Golab J. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol. 2005;52(2):339-52
6. Wang J-Y, Ho T, Trojanek J, Chintapalli J, Grabacka M, Stoklosa T, Garcia F-U, Skorski T, Reiss K. Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence. Oncogene 2005 May 26;24(23):3748-58

7. Adamek M, Krawczyk-Krupka A, Mostowy A, Czuba Z, Król W, Kasperczyk S, Jakóbisiak M, Gołąb J, Sieroń A. Topical ALA-PDT modifies neutrophils' chemiluminescence, lymphocytes' interleukin-1 beta secretion and serum level of transforming growth factor beta 1 in patients with non melanoma skin malignancies. A clinical study. Photodiagn. Photodyn. Ther. 2005 (in press)

8. Gołąb J, Stokłosa T, Technology evaluation: SB-485232. Curr. Opin. Mol. Ther. 2005; 7(1):85-93

2004

1. Stokłosa T., Słupianek A., Datta M., Nieborowska-Skorska M., Nowicki MO, Koptyra M. Skórski T. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle 2004, 3 (11), e93-e102

2. Nowicki MO., Faliński R., Koptyra M., Słupianek A., Stokłosa T., Gloc E., Nieborowska-Skorska M., Błasiak J., Skórski T. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species - dependent DNA double-strand breaks. Blood 2004, 104(12), 3746-3753;

3. Issat T, Nowis D, Jakóbisiak M, Gołąb J. Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncol Rep. 2004;12(6):1371-5.

4. Mrówka P, Gołąb J. Receptor NKG2D i jego ligandy. Post Biol Kom 2004; 31: 71-80.

5. Gołąb J, Bauer TM, Daniel V, Naujokat C. Role of the ubiquitin-proteasome pathway in the diagnosis of human diseases. Clin Chim Acta. 2004 Feb;340(1-2):27-40.
6. Młynarczuk I, Mróz P, Hoser G, Nowis D, Biały LP, Ziemba H, Grzela T, Feleszko W, Malejczyk J, Wójcik C, Jakóbisiak M, Gołąb J. AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. Leuk Res. 2004; 28: 53-61.

7. Kopeć M, Strusińska K, Legat M, Makowski M, Jakóbisiak M, Gołąb J. Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro. Oncol Rep. 2004; 11: 1127-1131.

8. Łazarczyk M, Grzela T, Niderla J, Łazarczyk MA, Milewski L, Dziunycz P, Skopiński P, Gołąb J. Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma-derived metastatic tumor development in lungs. Oncol Rep. 2004; 11: 1121-1125.

9. Kozar K, Kamiński R, Legat M, Kopeć M, Nowis D, Skierski JS, Koronkiewicz M, Jakóbisiak M, Gołąb J. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol. 2004; 24: 1149-1157.

10. Stoklosa T, Golab J, Wojcik C, Wlodarski P, Jalili A, Januszko P, Giermasz A, Wilczynski GM, Pleban E, Marczak M, Wilk S, Jakobisiak M. Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. Apoptosis. 2004 ;9: 193-204.
11. Lasek W, Basak G, Switaj T, Jakubowska AB, Wysocki PJ, Mackiewicz A, Drela N, Jalili A, Kaminski R, Kozar K, Jakobisiak M. Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother. 2004; 53: 363-372.

12. Świtaj T, Jalili A, Jakubowska AB, Drela N, Stoksik M, Nowis D, Basak G, Gołąb J, Wysocki PJ, Mackiewicz A, Sasor A, Socha-Urbanek K, Jakóbisiak M, Lasek W. CpG immunostimulatory oligodeoxynucleotide (ODN) 1826 enhances antitumor effec of IL-12 gene-modified vaccine in a melanoma model in mice. Clin Cancer Res 2004 Jun 15;10(12 Pt 1):4165-75.

13. Jalili A, Makowski M, Świtaj T, Nowis N, Wilczyński GM, Wilczek E, Chorąży-Massalska M, Radzikowska A, Maśliński W, Biały Ł, Sieńko J, Sieroń A, Adamek M, Basak G, Mróz P, Krasnodębski IW, Jakóbisiak M, Gołąb J. Effective photoimmunotherapy of murine colon carcinoma induced by the combinationn of photodynamic therapy and dendritic cells. Clin Cancer Res 2004 Jul 1;10(13):4498-508.

14. Kamiński R, Kozar K, Niderla J, Grzela T, Wilczyński G, Skierski JS, Koronkiewicz M, Jakóbisiak M, Gołąb J. Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. Oncol Rep 2004 (in press)

Strony